Abstract
The Papanicolaou (PAP) test is widely used to screen for cervical cancer. All high-grade lesions such as atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H), and high-grade squamous intraepithelial lesion, identified on a PAP test should be followed-up by a confirmatory cervical biopsy. In this review, we discuss the challenges in interpreting cervical tissue specimens and the various ancillary techniques used in the evaluation of cervical dysplasia. Ancillary studies include deeper levels, p16 immunohistochemistry (IHC), human papillomavirus (HPV) testing, and, importantly, cyto-histologic correlation. Of these, p16 IHC is consistently sensitive and specific for detecting HSIL. HPV RNA in situ hybridization (ISH) is a newer technique with excellent sensitivity and specificity for detecting virally infected cells and it may be more broadly applicable to both low- and high-grade squamous intraepithelial lesions.
References
1.
Bosch
X
, Harper
D
. Prevention strategies of cervical cancer in the HPV vaccine era
. Gynecol Oncol
. 2006
Oct
;103
(1
):21
–4
.
[PubMed]
0090-82582.
Bosch
FX
, Lorincz
A
, Muñoz
N
, Meijer
CJ
, Shah
KV
. The causal relation between human papillomavirus and cervical cancer
. J Clin Pathol
. 2002
Apr
;55
(4
):244
–65
.
[PubMed]
0021-97463.
Andrae
B
, Andersson
TM
, Lambert
PC
, Kemetli
L
, Silfverdal
L
, Strander
B
, et al Screening and cervical cancer cure: population based cohort study
. BMJ
. 2012
Mar
;344
mar01 2
:e900
.
[PubMed]
0959-81384.
Landy
R
, Pesola
F
, Castañón
A
, Sasieni
P
. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study
. Br J Cancer
. 2016
Oct
;115
(9
):1140
–6
.
[PubMed]
0007-09205.
National Cancer Institute Workshop
. The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses
. JAMA
. 1989
Aug
;262
(7
):931
–4
.
[PubMed]
0098-74846.
Nayar
R
, Wilbur
DC
. The bethesda system for reporting cervical cytology: Definitions, criteria, and explanatory notes
. Springer International Publishing
; 2015
.7.
Solomon
D
, Davey
D
, Kurman
R
, Moriarty
A
, O’Connor
D
, Prey
M
, et al; Bethesda 2001 Workshop
. The 2001 Bethesda System: terminology for reporting results of cervical cytology
. JAMA
. 2002
Apr
;287
(16
):2114
–9
.
[PubMed]
0098-74848.
Ho
GY
, Bierman
R
, Beardsley
L
, Chang
CJ
, Burk
RD
. Natural history of cervicovaginal papillomavirus infection in young women
. N Engl J Med
. 1998
Feb
;338
(7
):423
–8
.
[PubMed]
0028-47939.
Darragh
TM
, Colgan
TJ
, Thomas Cox
J
, Heller
DS
, Henry
MR
, Luff
RD
, et al; Members of the LAST Project Work Groups
. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology
. Int J Gynecol Pathol
. 2013
Jan
;32
(1
):76
–115
.
[PubMed]
0277-169110.
Davey
DD
, Neal
MH
, Wilbur
DC
, Colgan
TJ
, Styer
PE
, Mody
DR
. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology
. Arch Pathol Lab Med
. 2004
Nov
;128
(11
):1224
–9
.
[PubMed]
1543-216511.
Wright
TC
Jr, Cox
JT
, Massad
LS
, Twiggs
LB
, Wilkinson
EJ
; 2001 ASCCP-sponsored Consensus Conference
. 2001 Consensus Guidelines for the Management of Women with Cervical Cytological Abnormalities
. J Low Genit Tract Dis
. 2002
Apr
;6
(2
):127
–43
.
[PubMed]
1089-259112.
Massad
LS
, Einstein
MH
, Huh
WK
, Katki
HA
, Kinney
WK
, Schiffman
M
, et al; 2012 ASCCP Consensus Guidelines Conference
. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors
. J Low Genit Tract Dis
. 2013
Apr
;17
(5
Suppl 1
):S1
–27
.
[PubMed]
1089-259113.
Katki
HA
, Schiffman
M
, Castle
PE
, Fetterman
B
, Poitras
NE
, Lorey
T
, et al Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines
. J Low Genit Tract Dis
. 2013
Apr
;17
(5
Suppl 1
):S28
–35
.
[PubMed]
1089-259114.
McCredie
MR
, Paul
C
, Sharples
KJ
, Baranyai
J
, Medley
G
, Skegg
DC
, et al Consequences in women of participating in a study of the natural history of cervical intraepithelial neoplasia 3
. Aust N Z J Obstet Gynaecol
. 2010
Aug
;50
(4
):363
–70
.
[PubMed]
0004-866615.
McCredie
MR
, Sharples
KJ
, Paul
C
, Baranyai
J
, Medley
G
, Jones
RW
, et al Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study
. Lancet Oncol
. 2008
May
;9
(5
):425
–34
.
[PubMed]
1470-204516.
Crothers
BA
, Jones
BA
, Cahill
LA
, Moriarty
AT
, Mody
DR
, Tench
WD
, et al Quality improvement opportunities in gynecologic cytologic-histologic correlations: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 4
. Arch Pathol Lab Med
. 2013
Feb
;137
(2
):199
–213
.
[PubMed]
0003-998517.
Joste
NE
, Crum
CP
, Cibas
ES
. Cytologic/histologic correlation for quality control in cervicovaginal cytology. Experience with 1,582 paired cases
. Am J Clin Pathol
. 1995
Jan
;103
(1
):32
–4
.
[PubMed]
0002-917318.
Health CDo, Human Services HCFA: Clinical Laboratory improvement amendments of 1988: final rule. 57 Federal Register 7146 (1992) (codified at 42 CFR §493)
19.
George
GB
, Joe
W
. Walker, Jr
. Gynecologic Cytology-Histology Correlation Guideline, The ASC Bulletin
; 2017
.20.
Raab
SS
, Grzybicki
DM
. Cytologic-histologic correlation
. Cancer Cytopathol
. 2011
Oct
;119
(5
):293
–309
.
[PubMed]
1934-662X21.
Abdul-Karim
FW
, Yang
B
. Cytologic-Histologic Discrepancies in Pathology of the Uterine Cervix: Analysis of the Clinical and Pathologic Factors
. Adv Anat Pathol
. 2017
Sep
;24
(5
):304
–9
.
[PubMed]
1072-410922.
Gilani
SM
, Mazzara
PF
. Cytohistologic correlation in premenopausal and postmenopausal women
. Acta Cytol
. 2013
;57
(6
):575
–80
.
[PubMed]
0001-554723.
Chivukula
M
, Shidham
VB
. ASC-H in Pap test—definitive categorization of cytomorphological spectrum
. Cytojournal
. 2006
May
;3
(1
):14
.
[PubMed]
1742-641324.
Saad
RS
, Dabbs
DJ
, Kordunsky
L
, Kanbour-Shakir
A
, Silverman
JF
, Liu
Y
, et al Clinical significance of cytologic diagnosis of atypical squamous cells, cannot exclude high grade, in perimenopausal and postmenopausal women
. Am J Clin Pathol
. 2006
Sep
;126
(3
):381
–8
.
[PubMed]
0002-917325.
Patton
AL
, Duncan
L
, Bloom
L
, Phaneuf
G
, Zafar
N
. Atypical squamous cells, cannot exclude a high-grade intraepithelial lesion and its clinical significance in postmenopausal, pregnant, postpartum, and contraceptive-use patients
. Cancer
. 2008
Dec
;114
(6
):481
–8
.
[PubMed]
0008-543X26.
David
O
, Cabay
RJ
, Pasha
S
, Dietrich
R
, Leach
L
, Guo
M
, et al The role of deeper levels and ancillary studies (p16(Ink4a) and ProExC) in reducing the discordance rate of Papanicolaou findings of high-grade squamous intraepithelial lesion and follow-up cervical biopsies
. Cancer
. 2009
Jun
;117
(3
):157
–66
.
[PubMed]
0008-543X27.
Luo
YV
, Prihoda
TJ
, Sharkey
FE
. Number of levels needed for diagnosis of cervical biopsies
. Arch Pathol Lab Med
. 2002
Oct
;126
(10
):1205
–8
.
[PubMed]
0003-998528.
Reyes
MC
, Cooper
K
. Cervical cancer biopsy reporting: a review
. Indian J Pathol Microbiol
. 2014
Jul-Sep
;57
(3
):364
–8
.
[PubMed]
0377-492929.
Stoler
MH
. Human papillomaviruses and cervical neoplasia: a model for carcinogenesis
. Int J Gynecol Pathol
. 2000
Jan
;19
(1
):16
–28
.
[PubMed]
0277-169130.
Galgano
MT
, Castle
PE
, Atkins
KA
, Brix
WK
, Nassau
SR
, Stoler
MH
. Using biomarkers as objective standards in the diagnosis of cervical biopsies
. Am J Surg Pathol
. 2010
Aug
;34
(8
):1077
–87
.
[PubMed]
0147-518531.
Klaes
R
, Benner
A
, Friedrich
T
, Ridder
R
, Herrington
S
, Jenkins
D
, et al p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia
. Am J Surg Pathol
. 2002
Nov
;26
(11
):1389
–99
.
[PubMed]
0147-518532.
Singh
C
, Manivel
JC
, Truskinovsky
AM
, Savik
K
, Amirouche
S
, Holler
J
, et al Variability of pathologists’ utilization of p16 and ki-67 immunostaining in the diagnosis of cervical biopsies in routine pathology practice and its impact on the frequencies of cervical intraepithelial neoplasia diagnoses and cytohistologic correlations
. Arch Pathol Lab Med
. 2014
Jan
;138
(1
):76
–87
.
[PubMed]
0003-998533.
Stoler
MH
, Ronnett
BM
, Joste
NE
, Hunt
WC
, Cuzick
J
, Wheeler
CM
; New Mexico HPV Pap Registry Steering Committee
. The Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status
. Am J Surg Pathol
. 2015
Jun
;39
(6
):729
–36
.
[PubMed]
0147-518534.
Clinton
LK
, Miyazaki
K
, Ayabe
A
, Davis
J
, Tauchi-Nishi
P
, Shimizu
D
. The LAST guidelines in clinical practice: implementing recommendations for p16 use
. Am J Clin Pathol
. 2015
Dec
;144
(6
):844
–9
.
[PubMed]
0002-917335.
Maniar
KP
, Sanchez
B
, Paintal
A
, Gursel
DB
, Nayar
R
. Role of the Biomarker p16 in Downgrading -IN 2 Diagnoses and Predicting Higher-grade Lesions
. Am J Surg Pathol
. 2015
Dec
;39
(12
):1708
–18
.
[PubMed]
0147-518536.
Zhang
G
, Yang
B
, Abdul-Karim
FW
. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing
. Int J Gynecol Pathol
. 2015
Mar
;34
(2
):180
–6
.
[PubMed]
0277-169137.
Jackson
JA
, Kapur
U
, Erşahin
Ç
. Utility of p16, Ki-67, and HPV test in diagnosis of cervical intraepithelial neoplasia and atrophy in women older than 50 years with 3- to 7-year follow-up
. Int J Surg Pathol
. 2012
Apr
;20
(2
):146
–53
.
[PubMed]
1066-896938.
Rodríguez-Trujillo
A
, Martí
C
, Angeles
MA
, Sierra
A
, Esteve
R
, Saco
A
, et al Value of HPV 16/18 Genotyping and p16/Ki-67 Dual Staining to Predict Progression to HSIL/CIN2+ in Negative Cytologies From a Colposcopy Referral Population
. Am J Clin Pathol
. 2018
Oct
;150
(5
):432
–40
.
[PubMed]
0002-917339.
Huh
WK
, Ault
KA
, Chelmow
D
, Davey
DD
, Goulart
RA
, Garcia
FA
, et al Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance
. Obstet Gynecol
. 2015
Feb
;125
(2
):330
–7
.
[PubMed]
0029-784440.
Saslow
D
, Solomon
D
, Lawson
HW
, Killackey
M
, Kulasingam
SL
, Cain
JM
, et al American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
. J Low Genit Tract Dis
. 2012
Jul
;16
(3
):175
–204
.
[PubMed]
1089-259141.
Malila
N
, Leinonen
M
, Kotaniemi-Talonen
L
, Laurila
P
, Tarkkanen
J
, Hakama
M
. The HPV test has similar sensitivity but more overdiagnosis than the Pap test—a randomised health services study on cervical cancer screening in Finland
. Int J Cancer
. 2013
May
;132
(9
):2141
–7
.
[PubMed]
0020-713642.
Xu
L
, Verdoodt
F
, Wentzensen
N
, Bergeron
C
, Arbyn
M
. Triage of ASC-H: A meta-analysis of the accuracy of high-risk HPV testing and other markers to detect cervical precancer
. Cancer Cytopathol
. 2016
Apr
;124
(4
):261
–72
.
[PubMed]
1934-662X43.
Cohen
D
, Austin
RM
, Gilbert
C
, Freij
R
, Zhao
C
. Follow-up outcomes in a large cohort of patients with human papillomavirus-negative ASC-H cervical screening test results
. Am J Clin Pathol
. 2012
Oct
;138
(4
):517
–23
.
[PubMed]
0002-917344.
Bandyopadhyay
S
, Austin
RM
, Dabbs
D
, Zhao
C
. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results
. Arch Pathol Lab Med
. 2008
Dec
;132
(12
):1874
–81
.
[PubMed]
1543-216545.
Mills
AM
, Dirks
DC
, Poulter
MD
, Mills
SE
, Stoler
MH
. HR-HPV E6/E7 mRNA In Situ Hybridization: Validation Against PCR, DNA In Situ Hybridization, and p16 Immunohistochemistry in 102 Samples of Cervical, Vulvar, Anal, and Head and Neck Neoplasia
. Am J Surg Pathol
. 2017
May
;41
(5
):607
–15
.
[PubMed]
0147-518546.
Evans
MF
, Peng
Z
, Clark
KM
, Adamson
CS
, Ma
XJ
, Wu
X
, et al HPV E6/E7 RNA in situ hybridization signal patterns as biomarkers of three-tier cervical intraepithelial neoplasia grade
. PLoS One
. 2014
Mar
;9
(3
):e91142
.
[PubMed]
1932-620347.
Kong
CS
, Balzer
BL
, Troxell
ML
, Patterson
BK
, Longacre
TA
. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia
. Am J Surg Pathol
. 2007
Jan
;31
(1
):33
–43
.
[PubMed]
0147-518548.
Coppock
JD
, Willis
BC
, Stoler
MH
, Mills
AM
. HPV RNA in situ hybridization can inform cervical cytology-histology correlation
. Cancer Cytopathol
. 2018
Aug
;126
(8
):533
–40
.
[PubMed]
1934-662X49.
Rodríguez-Carunchio
L
, Soveral
I
, Steenbergen
RD
, Torné
A
, Martinez
S
, Fusté
P
, et al HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis
. BJOG
. 2015
Jan
;122
(1
):119
–27
.
[PubMed]
1470-032850.
Tawe
L
, Grover
S
, Narasimhamurthy
M
, Moyo
S
, Gaseitsiwe
S
, Kasvosve
I
, et al Molecular detection of human papillomavirus (HPV) in highly fragmented DNA from cervical cancer biopsies using double-nested PCR
. MethodsX
. 2018
May
;5
:569
–78
.
[PubMed]
2215-016151.
Castro
FA
, Koshiol
J
, Quint
W
, Wheeler
CM
, Gillison
ML
, Vaughan
LM
, et al Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods
. BMC Infect Dis
. 2015
Nov
;15
(1
):544
.
[PubMed]
1471-233452.
Abreu
AL
, Souza
RP
, Gimenes
F
, Consolaro
ME
. A review of methods for detect human Papillomavirus infection
. Virol J
. 2012
Nov
;9
(1
):262
.
[PubMed]
1743-422X53.
Pirog
EC
. Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors
. Arch Pathol Lab Med
. 2017
Dec
;141
(12
):1653
–67
.
[PubMed]
0003-9985© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
